The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems.

By H. Walczak, P. Krammer. Experimental Cell Research, 2000

672 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/ee3b81fd7f9d2ddcb953e2ce628a37c776af66db

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Bryan R. G. Williams
2. K. Debatin
3. Karen H. Vousden
4. G. Evan
5. Harald Wajant
6. Simone Fulda

In Molecular Biology

1. Simone Fulda
2. S. Khosla
3. G. Evan
4. K. Debatin
5. D. Lacey
6. W. J. Boyle
7. Karen H. Vousden
8. I. Schemainda

Citations in the corpus

• Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy (2006, background): “The corresponding ligands of the TNF superfamily comprise death receptor ligands such as CD95 ligand (CD95L), TNFa, lymphotoxin-a (the later two bind to TNFRI), TRAIL and TWEAK, a ligand for DR3 (Walczak and Krammer, 2000).”
• Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. (2003, background): “One potential confounder was binding of the OPG-Fc-FITC to TRAIL, a related TNF family member with potent apoptosis-inducing properties that is expressed on surfaces of many cell types (38, 39).”
• Functional classification of interferon‐stimulated genes identified using microarrays (2001, background): “The TNFRSF6 protein is a death receptor protein involved in signaling T-cell killing [76], while the TNFSF10 protein is a soluble TNF-like molecule involved in the induction of apoptosis when it binds its receptor [78].”
• NF-κB Inducers Upregulate cFLIP, a Cycloheximide-Sensitive Inhibitor of Death Receptor Signaling (2001, background): “were the imprinted gene IPL (TDAG51), known to couple T-cell receptor (TCR) signaling to Fas expression in activation-induced cell death (21, 27), and TRAIL-R2 (DR5/ TRICK2/Killer), one of the two death domain-containing receptors for TRAIL (38).”
• FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. (2003, background): “demise of cells in a controlled way (8, 9).”
• Proliferation, cell cycle and apoptosis in cancer (2001, background): “One such pathway is mediated by transmembrane death receptors of the CD95 (Apo-1 or Fas)/TRAIL/tumour-necrosis factor (TNF) receptor 1 family, whose ligation triggers recruitment and assembly of multiprotein complexes that activate apical caspase 8 (ref”